Meeting
2020 ASCO Virtual Scientific Program
Pyrotinib plus capecitabine for HER2-positive, trastuzumab-resistant metastatic breast cancer: A pooled analysis of three randomized controlled trials.
Authors
Zefei Jiang
The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
Zefei Jiang , Binghe Xu , Min Yan , Quchang Ouyang , Xi-Chun Hu , Wei Li , Ji Feng Feng , Qingyuan Zhang , Zhongsheng Tong , Ping Yan , Xiaoyu Zhu , Shangyi Rong , Jianjun Zou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1048)
DOI
10.1200/JCO.2020.38.15_suppl.1048
Abstract #
1048
Poster Bd #
133
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
First Author: Min Yan
Poster
2011 Breast Cancer Symposium
Correlation of efficacy between rash and lapatinib/capecitabine therapy in Japanese HER2-positive metastatic breast cancer patients.
First Author: S. E. Nagai
Poster
2022 ASCO Annual Meeting
Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer.
First Author: Xiuwen Guan
Poster
2018 ASCO Annual Meeting
Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.
First Author: Ander Urruticoechea